| pubmed-article:15581045 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0679729 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C1518578 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0004927 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0728747 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:15581045 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15581045 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15581045 | pubmed:dateCreated | 2004-12-7 | lld:pubmed |
| pubmed-article:15581045 | pubmed:abstractText | Advanced breast cancer (ABC) is an incurable disease. Standard first-line treatment for patients with HER-2/neu overexpressing tumors includes the combination of the humanized monoclonal antibody trastuzumab with chemotherapy, mainly paclitaxel. This combination is the first to demonstrate a survival advantage in this group of patients. To improve on these results, we investigated a triplet, paclitaxel-gemcitabine-trastuzumab (TGH), in a phase II study. | lld:pubmed |
| pubmed-article:15581045 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15581045 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15581045 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15581045 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15581045 | pubmed:issn | 0735-7907 | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:KalofonosHara... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:FountzilasGeo... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:AravantinosGe... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:SkarlosDimost... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:TsavdaridisDi... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:PapakostasPav... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:GogasHelenH | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:Kalogera-Foun... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:Christodoulou... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:RazisEvangeli... | lld:pubmed |
| pubmed-article:15581045 | pubmed:author | pubmed-author:KarinaMariaM | lld:pubmed |
| pubmed-article:15581045 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15581045 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:15581045 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15581045 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15581045 | pubmed:pagination | 655-62 | lld:pubmed |
| pubmed-article:15581045 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:meshHeading | pubmed-meshheading:15581045... | lld:pubmed |
| pubmed-article:15581045 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15581045 | pubmed:articleTitle | Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). | lld:pubmed |
| pubmed-article:15581045 | pubmed:affiliation | 1 st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. hecogoff@otenet.gr | lld:pubmed |
| pubmed-article:15581045 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15581045 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15581045 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15581045 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15581045 | lld:pubmed |
